NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
2.29
Dollar change
-0.11
Percentage change
-4.58
%
Index- P/E- EPS (ttm)-12.26 Insider Own0.00% Shs Outstand2.81M Perf Week-6.91%
Market Cap11.76M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-2.97%
Enterprise Value20.37M PEG- EPS next Q- Inst Own49.38% Short Float- Perf Quarter-68.02%
Income-26.61M P/S- EPS this Y- Inst Trans8.10% Short Ratio1.40 Perf Half Y-89.10%
Sales0.00M P/B0.81 EPS next Y- ROA-102.64% Short Interest0.27M Perf YTD-80.91%
Book/sh2.84 P/C6.12 EPS next 5Y- ROE-238.64% 52W High66.60 -96.56% Perf Year-93.42%
Cash/sh0.37 P/FCF- EPS past 3/5Y17.72% 6.84% ROIC-164.45% 52W Low1.98 15.66% Perf 3Y-98.47%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.74% 10.90% Perf 5Y-99.49%
Dividend TTM- EV/Sales- EPS Y/Y TTM35.03% Oper. Margin- ATR (14)0.33 Perf 10Y-99.54%
Dividend Ex-DateAug 28, 1996 Quick Ratio0.39 Sales Y/Y TTM- Profit Margin- RSI (14)31.38 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.55 EPS Q/Q44.20% SMA20-4.94% Beta0.30 Target Price300.00
Payout- Debt/Eq1.32 Sales Q/Q- SMA50-53.03% Rel Volume0.66 Prev Close2.40
Employees- LT Debt/Eq1.02 EarningsMay 15 BMO SMA200-84.33% Avg Volume192.42K Price2.29
IPODec 08, 1983 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume129,252 Change-4.58%
Date Action Analyst Rating Change Price Target Change
Jan-13-20Initiated H.C. Wainwright Buy $18
Mar-02-15Initiated Dawson James Buy $3
Jun-18-25 09:00AM
May-23-25 04:05PM
May-21-25 08:14PM
04:05PM
08:00AM
02:40PM Loading…
May-19-25 02:40PM
May-15-25 09:00AM
May-14-25 07:30PM
Apr-23-25 08:30AM
Apr-14-25 10:15AM
Apr-08-25 09:51AM
Mar-24-25 09:00AM
Mar-18-25 04:05PM
Mar-17-25 03:24PM
08:00AM
08:30AM Loading…
Mar-14-25 08:30AM
Feb-20-25 08:00AM
Feb-18-25 08:30AM
Feb-14-25 04:24PM
Jan-14-25 09:00AM
Dec-31-24 04:05PM
Dec-29-24 08:41PM
Dec-27-24 05:05PM
Dec-12-24 09:15AM
Nov-07-24 08:15AM
Oct-22-24 09:15AM
Oct-01-24 06:00AM
Sep-16-24 07:30AM
Sep-10-24 09:32AM
Sep-04-24 09:00AM
08:00AM Loading…
Aug-15-24 08:00AM
05:09AM
Jul-29-24 04:05PM
Jul-26-24 11:52AM
08:23AM
Jul-08-24 09:15AM
Jun-18-24 08:00AM
Jun-06-24 07:00AM
May-16-24 09:08AM
09:00AM
May-08-24 04:02PM
09:00AM
Apr-23-24 09:00AM
Mar-19-24 09:00AM
Mar-06-24 08:45AM
Feb-15-24 08:00AM
Feb-14-24 05:11PM
Feb-13-24 12:00PM
Feb-09-24 08:30AM
Feb-06-24 09:00AM
Jan-31-24 09:00AM
Dec-22-23 08:00AM
Dec-04-23 08:30AM
Nov-20-23 04:15PM
Nov-16-23 08:30AM
Nov-09-23 08:52AM
Oct-30-23 09:20AM
Oct-24-23 08:00AM
Oct-23-23 09:15AM
Oct-19-23 08:00AM
Oct-09-23 07:50AM
Oct-05-23 08:45AM
Sep-26-23 09:00AM
Aug-11-23 08:07AM
08:00AM
Jul-31-23 05:49AM
Jul-20-23 11:36AM
Jul-17-23 09:23PM
04:05PM
Jul-14-23 09:15AM
Jul-11-23 08:45AM
Jun-22-23 10:19AM
May-16-23 09:17AM
May-15-23 02:18PM
09:00AM
May-12-23 04:35PM
04:30PM
Apr-27-23 09:12PM
Apr-19-23 09:00AM
Mar-08-23 09:00AM
Mar-03-23 09:00AM
Feb-27-23 05:26AM
Feb-15-23 09:00AM
Jan-03-23 11:57AM
Dec-28-22 09:00AM
Nov-22-22 12:21PM
09:00AM
Oct-17-22 08:50AM
Sep-12-22 09:00AM
Sep-07-22 08:45AM
Aug-24-22 05:45AM
Aug-19-22 08:45AM
Aug-15-22 09:00AM
Aug-08-22 08:45AM
Jul-14-22 10:00AM
Jun-08-22 09:00AM
05:25AM
Jun-07-22 07:30AM
May-27-22 09:00AM
May-19-22 05:10AM
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.